论文部分内容阅读
目的:观察并评估地奥司明片联合盐酸坦索罗辛缓释胶囊治疗Ⅲ_B型前列腺炎的临床疗效及用药安全。方法:将162例Ⅲ_B型前列腺炎患者随机分成对照组和观察组两组,对照组患者予以盐酸坦索罗辛缓释胶囊治疗,观察组予以地奥司明片联合盐酸坦索罗辛缓释胶囊治疗,治疗前及治疗后2个月分别对所有患者进行美国国立卫生研究院慢性前列腺炎症状指数评分(NIH-CPSI),包括疼痛不适评分、排尿症状评分以及生活质量评分,比较两组的临床疗效及不良反应的发生情况。结果:对照组及观察组患者经过治疗以后NIH-CPSI评分结果均较治疗前明显改善,其差异有统计学意义(P<0.05);其中观察组的总体显效率及总体有效率均较对照组显著升高(P<0.05),而不良反应发生率差异无统计学意义(P>0.05)。结论:地奥司明片联合盐酸坦索罗辛缓释胶囊治疗Ⅲ_B型前列腺炎较坦索罗辛单药治疗效果更为显著,能显著提高临床疗效,改善患者生活质量,而不显著增加不良反应的发生率,具有很大的临床推广及应用价值。
OBJECTIVE: To observe and evaluate the clinical efficacy and safety of gemcitabine combined with tamsulosin hydrochloride sustained-release capsules in the treatment of type Ⅲ_B prostatitis. Methods: A total of 162 patients with type Ⅲ_B prostatitis were randomly divided into control group and observation group. Patients in the control group were treated with tamsulosin hydrochloride sustained-release capsules. The observation group was treated with gemcitabine combined with sustained release of tamsulosin hydrochloride Capsule treatment, before treatment and 2 months after treatment were all NIH-CPSI symptoms index scores (NIH-CPSI), including pain discomfort score, voiding symptom scores and quality of life scores were compared between the two groups Clinical efficacy and adverse reactions occurred. Results: The results of NIH-CPSI score after treatment in control group and observation group were significantly improved compared with that before treatment (P <0.05), and the overall effective rate and total effective rate in observation group were significantly higher than those in control group (P <0.05), while the incidence of adverse reactions was not significantly different (P> 0.05). Conclusion: Diosmin tablets combined with tamsulosin hydrochloride sustained-release capsules in the treatment of type Ⅲ_B prostatitis more effective than tamsulosin monotherapy, significantly improve the clinical efficacy and improve the quality of life of patients without significant increase in adverse The incidence of the reaction, with great clinical promotion and application value.